Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

A research team led by Prof. WENG Jianping from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences (CAS) revealed that insulin-like growth factor-binding ...

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a report released on ...

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT ... the analyst tells investors in a research note. The firm says it is “incredibly bullish” around the profile ...

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is expected to announce its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...